- Home
- GNLX vs CRVS Comparison
GNLX vs CRVS Comparison
Compare GNLX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- CRVS
- Stock Information
- Founded
- GNLX 2001
- CRVS 2014
- Country
- GNLX United States
- CRVS United States
- Employees
- GNLX N/A
- CRVS N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- CRVS Health Care
- Exchange
- GNLX Nasdaq
- CRVS Nasdaq
- Market Cap
- GNLX 184.4M
- CRVS 206.5M
- IPO Year
- GNLX 2023
- CRVS 2016
- Fundamental
- Price
- GNLX $2.96
- CRVS $4.43
- Analyst Decision
- GNLX Strong Buy
- CRVS Strong Buy
- Analyst Count
- GNLX 4
- CRVS 3
- Target Price
- GNLX $17.75
- CRVS $16.33
- AVG Volume (30 Days)
- GNLX 138.3K
- CRVS 1.4M
- Earning Date
- GNLX 05-06-2025
- CRVS 05-08-2025
- Dividend Yield
- GNLX N/A
- CRVS N/A
- EPS Growth
- GNLX N/A
- CRVS N/A
- EPS
- GNLX N/A
- CRVS N/A
- Revenue
- GNLX N/A
- CRVS N/A
- Revenue This Year
- GNLX N/A
- CRVS N/A
- Revenue Next Year
- GNLX N/A
- CRVS N/A
- P/E Ratio
- GNLX N/A
- CRVS N/A
- Revenue Growth
- GNLX N/A
- CRVS N/A
- 52 Week Low
- GNLX $1.60
- CRVS $1.75
- 52 Week High
- GNLX $5.89
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- GNLX 54.28
- CRVS 68.59
- Support Level
- GNLX $2.26
- CRVS $3.17
- Resistance Level
- GNLX $3.06
- CRVS $3.71
- Average True Range (ATR)
- GNLX 0.31
- CRVS 0.23
- MACD
- GNLX 0.04
- CRVS 0.08
- Stochastic Oscillator
- GNLX 78.42
- CRVS 95.47
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).